Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Connolly

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|November 14, 2017
Restrictive or Liberal Red-Cell Transfusion for Cardiac SurgeryC David Mazer, Richard P Whitlock, Dean A Fergusson, et al.
The New England Journal of Medicine|August 28, 2018
Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac SurgeryC David Mazer, Richard P Whitlock, Dean A Fergusson, et al.
American Heart Journal|June 1, 2020
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillationGanesan Karthikeyan, Stuart J Connolly, Mpiko Ntsekhe, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The New England Journal of Medicine|November 14, 2017
Restrictive or Liberal Red-Cell Transfusion for Cardiac SurgeryC David Mazer, Richard P Whitlock, Dean A Fergusson, et al.
The New England Journal of Medicine|August 28, 2018
Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac SurgeryC David Mazer, Richard P Whitlock, Dean A Fergusson, et al.
American Heart Journal|June 1, 2020
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillationGanesan Karthikeyan, Stuart J Connolly, Mpiko Ntsekhe, et al.
Pageof 2